Cargando…

Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab

INTRODUCTION: Up to 60% of patients with metastatic melanoma develop melanoma brain metastasis (MBM) during the course of their disease. Surgery, radiosurgery (SRS), stereotactic radiotherapy (SRT), and whole‐brain radiation therapy (WBRT) or combinations of these are commonly used local treatment m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du Four, Stephanie, Janssen, Yanina, Michotte, Alex, Van Binst, Anne‐Marie, Van den Begin, Robbe, Duerinck, Johnny, Neyns, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198218/ https://www.ncbi.nlm.nih.gov/pubmed/30133176 http://dx.doi.org/10.1002/cam4.1726

Ejemplares similares

Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients
por: Du Four, Stephanie, et al.
Publicado: (2014)

Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series
por: Tijtgat, Jens, et al.
Publicado: (2023)

Pembrolizumab for the treatment of uveal melanoma: A case series
por: Jansen, Yanina Jeanne Leona, et al.
Publicado: (2020)

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
por: Awada, Gil, et al.
Publicado: (2020)

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
por: Pombo Antunes, Ana Rita, et al.
Publicado: (2020)

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
por: de Filette, Jeroen, et al.
Publicado: (2016)

Pituitary carcinoma - case series and review of the literature
por: Du Four, Stephanie, et al.
Publicado: (2022)

An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals
por: Huylebrouck, M., et al.
Publicado: (2012)

Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives
por: Duerinck, Johnny, et al.
Publicado: (2023)

Ipilimumab and radiation therapy for melanoma brain metastases
por: Silk, Ann W, et al.
Publicado: (2013)

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery
por: Tazi, Karim, et al.
Publicado: (2015)

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
por: Wilgenhof, Sofie, et al.
Publicado: (2012)

Predictive value of a nomogram for melanomas with brain metastases at initial diagnosis
por: Liu, Hong, et al.
Publicado: (2019)

Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
por: Duerinck, Johnny, et al.
Publicado: (2021)

Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1
por: Awada, Gil, et al.
Publicado: (2020)

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma
por: Samlowski, Wolfram E., et al.
Publicado: (2017)

Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases
por: Moyers, Justin T., et al.
Publicado: (2021)

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
por: Awada, Gil, et al.
Publicado: (2021)

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
por: Niessner, Heike, et al.
Publicado: (2013)

Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report
por: Lambert, Ine, et al.
Publicado: (2021)

Dynamic contrast‐enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases
por: Hatzoglou, Vaios, et al.
Publicado: (2017)

MITF reprograms the extracellular matrix and focal adhesion in melanoma
por: Dilshat, Ramile, et al.
Publicado: (2021)

Midlife brain metastases in the United States: Is male at risk?
por: Che, Wenqiang, et al.
Publicado: (2022)

Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy—A retrospective cohort study
por: Gatterbauer, Brigitte, et al.
Publicado: (2020)

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
por: Vermeulen, Sim, et al.
Publicado: (2021)

AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells
por: Maenhout, Sarah K., et al.
Publicado: (2014)

In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases
por: Clark, Paul A, et al.
Publicado: (2020)

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
por: Rozeman, Elisa A, et al.
Publicado: (2023)

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment
por: Anderson, Erik S., et al.
Publicado: (2017)

First follow‐up radiographic response is one of the predictors of local tumor progression and radiation necrosis after stereotactic radiosurgery for brain metastases
por: Sharma, Mayur, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
por: Schlam, Ilana, et al.
Publicado: (2022)

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
por: Blake, Zoë, et al.
Publicado: (2018)

Characterization of the melanoma brain metastatic niche in mice and humans
por: Amit, Moran, et al.
Publicado: (2013)

A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases
por: Van Bael, Kobe, et al.
Publicado: (2015)

Brain Tumor Microenvironment and Angiogenesis in Melanoma Brain Metastases
por: Trembath, Dimitri G., et al.
Publicado: (2021)

Keratoacanthoma-appearing melanoma metastases in a patient receiving pembrolizumab therapy
por: Schopper, Heather, et al.
Publicado: (2016)

Development and Validation of a Predictive Model for Metastatic Melanoma Patients Treated with Pembrolizumab Based on Automated Analysis of Whole-Body [(18)F]FDG PET/CT Imaging and Clinical Features
por: Dirks, Ine, et al.
Publicado: (2023)

Risk factors for brain metastases in patients with non–small‐cell lung cancer
por: An, Ning, et al.
Publicado: (2018)

Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis
por: Dodoo, Grace N, et al.
Publicado: (2023)

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
por: Gibney, Geoffrey T, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7htb2r8ofohbsapcpsnl2hhvfu